Who Should Not Take Bioidentical Progesterone?
Bioidentical progesterone is absolutely contraindicated in women with current or history of breast cancer, unexplained vaginal bleeding, active venous thromboembolism (VTE) or pulmonary embolism, active arterial thromboembolic disease (stroke, MI), active liver disease, known hypersensitivity to progesterone or peanut oil (as most formulations contain peanut oil), and pregnancy. 1
Absolute Contraindications (Never Use)
The FDA-approved drug label for progesterone capsules explicitly lists the following as contraindications 1:
- Current, past, or suspected breast cancer - This is reinforced by multiple guidelines 2, 3 and recent research emphasizing that women with ER+ breast cancer or history of breast cancer should not take sex hormones including progesterone 4
- Unexplained abnormal genital bleeding - Must be evaluated before initiating therapy 2, 3, 1
- Active deep vein thrombosis, pulmonary embolism, or history of these conditions 1
- Active arterial thromboembolic disease (stroke, myocardial infarction) or history of these conditions 2, 1
- Known liver dysfunction or active liver disease 2, 1
- Known hypersensitivity to progesterone or its ingredients - Critical note: progesterone capsules contain peanut oil and should never be used by patients with peanut allergy 1
- Known or suspected pregnancy 1
- Untreated endometrial hyperplasia 2
Additional High-Risk Populations Requiring Extreme Caution
Beyond absolute contraindications, the following groups should generally avoid bioidentical progesterone or only use it after specialist consultation:
Malignancy-Related Concerns
- Known or suspected estrogen-sensitive malignant conditions including endometrial cancer 2
- Women at high risk for breast cancer (BRCA1/2 mutations, strong family history) should avoid exogenous sex hormones and proceed with extreme caution 4
Cardiovascular Risk Factors
- Untreated hypertension 2 - must be controlled before initiating therapy
- History of cerebrovascular accidents - stroke risk increases with hormone therapy in age-dependent manner 2, 5
- Documented thrombophilia - requires hematology consultation before any hormone therapy 6
Metabolic Conditions
- Porphyria cutanea tarda - this is an absolute contraindication 2
- Active gallbladder disease - exercise caution 3
- Severe hypertriglyceridemia - requires careful monitoring 3
Important Clinical Nuances
The 2017 AACE position statement specifically recommends against custom compounded "bioidentical hormone therapy" 7, 5, though FDA-approved bioidentical progesterone preparations (like micronized progesterone) may be considered with appropriate patient selection 7, 5.
When progesterone is necessary for endometrial protection in women using estrogen therapy, micronized progesterone is considered the safer alternative compared to synthetic progestins 7. Recent evidence suggests micronized progesterone does not increase breast cancer risk for up to 5 years of use, unlike synthetic progestins which show increased risk 8, 9.
Special Populations Requiring Individualized Assessment
- Women with migraine - particularly migraine with aura; transdermal routes may be safer 10
- Obese women - transdermal routes preferred 10
- History of endometriosis - may reactivate disease 10
- Diabetes mellitus - requires careful cardiovascular risk assessment 3
Common Pitfalls to Avoid
- Failing to screen for peanut allergy before prescribing progesterone capsules - this can cause anaphylaxis 1
- Starting thyroid hormone replacement before excluding adrenal insufficiency in women with multiple pituitary hormone deficiencies 11
- Assuming all "bioidentical" preparations are equivalent - only FDA-approved formulations have standardized dosing and quality control 7, 5, 2
- Not distinguishing between micronized progesterone and synthetic progestins - they have different risk profiles, particularly for breast cancer 8, 9
The key principle is that progesterone contraindications mirror those for estrogen-containing hormone therapy, with the critical addition of peanut allergy for most oral formulations. Risk assessment must prioritize cardiovascular disease, venous thromboembolism, and hormone-sensitive cancers as the primary concerns affecting morbidity and mortality 2, 3, 1.